Bluejay Therapeutics has developed therapeutic medicines that focus on reducing viral surface antigen monoclonal antibodies for the restoration of adaptive immunity and offer cures for people with viral and liver diseases, starting with CHB and CHD, enabling patients to improve their immunity and recover from infection. View on: LinkedIn.com | Sales Navigator.

New Funding Raised: $182M, Series C

Round Investors: Frazier Life Sciences (lead), Arkin Bio Ventures, RA Capital Management, T. Rowe Price

🚀Growth Focus: Accelerate the clinical development of BJT-778, as the treatment for HDV and support the progression of promising candidates in its robust pipeline for chronic hepatitis B.

Press: GlobeNewswire, FinSMEs

HQ: San Francisco, CA

Industry: Biotechnology Research

Employee Count: 18 (⚡13% increase in last 6 months)

Aardvark Therapeutics operates small molecule therapeutics that offer a first-in-class oral composition that selectively disrupts hunger signaling, regulates energy homeostasis, and does not interfere with nutrient absorption, allowing clinicians with an effective and safe treatment for obesity-related diseases. View on: LinkedIn.com | Sales Navigator.

New Funding Raised: $85M, Series C

Round Investors: The Prader-Willi Syndrome Association – USA, Cormorant Asset Management, The Foundation for Prader-Willi Research, Walleye Capital

🚀Growth Focus: Support the advancement of ARD-101’s potential in combating obesity, alongside propelling other critical pipeline programs

Press: PR Newswire, Silicon Valley Journals

HQ: San Diego, CA

Industry: Pharmaceutical Manufacturing

Employee Count: 14